CfPA-The Center for Professional Advancement, Amsterdam, The Netherlands
21-22 October 2019
Who Should Attend?
This course is intended for those responsible for ensuring compliance of excipients with the pharmacopoeias and regulatory authorities, and is applicable to pharmaceutical and excipient manufacturers and excipient distributors within the OTC, generic, innovator, biotechnology, consumer-care, and related industries. This course will benefit individuals in:
• Compendial affairs
• Regulatory affairs/CMC
• Quality assurance/Quality control
• Analytical chemistry
• R&D/product development/Formulation/Method development
• Product management/marketing Course Description
|
|
|
Invited Speakers:
|
|
 Irwin Silverstein, Ph.D., Consultant to the pharmaceutical industry |
Irwin Silverstein has been a consultant to the pharmaceutical industry since 2000. His career included 17 years as the head of corporate quality for ISP, a specialty chemical manufacturer that produced excipients and Active Pharmaceutical Ingredients. Since leaving ISP, he works as a consultant and was the Chief Operating Officer of International Pharmaceutical Excipients Auditing (IPEA) from incorporation until sale in 2014. During this time, IPEA was accredited by ANSI for their Excipient GMP Conformance Certification Program. He has been a subcontractor to a consulting firm hired as expert consultants by pharmaceutical firms in consent decree with FDA. Currently, he has continued to work with the International Pharmaceutical Excipients Council of the Americas (IPEC) since their founding in 1991 and has been involved in the development of excipient GMPs and related guidelines. He is on the NSF Standards Writing Committee that developed the NSF/IPEC/ANSI 363 Good Manufacturing Practices for Pharmaceutical Excipients ANSI standard. He is also the chair of the IPEC Learning Lab with responsibility for development of synchronous and asynchronous learning including workshops, webinars and eLearning.
Dr. Silverstein has authored many articles on excipient GMP compliance in magazines such as Pharmaceutical Technology, Tablets and Capsules, and Pharmaceutical Outsourcing. He has been a frequent presenter at conferences involving excipient regulatory compliance including ExcipientFest, ASQ Spring Conference, IVT and RAPs. He possesses a Ph.D. in organic chemistry and is an ASQ Certified Quality Auditor (CQA).
 J. Mark Wiggins; Owner and Compendial Consultant, Global Pharmacopoeia Solutions LLC |
J. Mark Wiggins is Owner and Compendial Consultant with Global Pharmacopoeia Solutions LLC, which he formed after more than 30 years’ experience in the pharmaceutical industry. He is also Pharmacopoeia Editor for the on-line publication International Pharmaceutical Quality. He was previously Director of Compendial Affairs at Merck & Co., Inc., (known as MSD outside the US and Canada), with more than 15 years’ experience optimizing the processes for review and response to compendial changes from around the world to enable quality and regulatory compliance. Mr. Wiggins has been an active participant in compendial harmonization, represented PhRMA on ICH Q4B, authored several papers, and was an invited speaker at international meetings with pharmacopoeias and regulators in the US, UK, Europe, India, Japan, Korea, and China.
|
|
Compliance with compendial requirements is a legal and regulatory requirement in those countries in which a pharmacopoeia is specified. While there is good awareness of compendial requirements for drug products and APIs, there is less understanding by excipient manufacturers related to confirmation the excipient meets the pharmacopoeia monograph.
This comprehensive 2-day course includes an introduction to the pharmacopoeias, with an emphasis on the USP-NF and Ph. Eur. A global perspective which touches on other pharmacopeias is presented. Details of the content, organization and use of the pharmacopoeias are covered, along with regulatory considerations for excipients. The course reviews practical examples of compliance with compendial requirements, as published by pharmacopoeias. In addition, there is exploration of the development and revision processes for compendial monographs with real-life case studies, along with a review of efforts toward compendial harmonization by IPEC, the Pharmacopoeial Discussion Group (PDG), and the International Conference on Harmonisation (ICH). The course concludes with an exploration of approaches to compendial surveillance, opportunities for advocacy, and ultimately, compliance with the requirements in the pharmacopoeias.
The course will assist the global bio/pharmaceutical industry; including innovator, generic, biotechnology, Contract Manufacturer, and consumer-care companies, seeking greater understanding of compliance requirements for excipient suppliers, particularly with the USP-NF and Ph. Eur.